Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.
Ranibizumab versus bevacizumab for ophthalmic diseases related to neovascularisation: a meta-analysis of randomised controlled trials.
复制标题
雷珠单抗与贝伐单抗治疗与新生血管相关的眼科疾病：随机对照试验的荟萃分析
DOI：
10.1371/journal.pone.0101253
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Li J
中科院分区：
文献类型：
--
作者：
Wu B;Wu H;Liu X;Lin H;Li J
贝伐单抗被认为与眼科疾病一样有效和安全。
在没有限制的情况下，对PubMed和Embase进行了搜索。
与Bevacizumab相比，涉及2,289名参与者的九个独立的随机对照临床试验（RCT）。失去≤15个字母为1.10（95％CI 0.90–1.33），0.93 （95％CI 0.77–1.11），0.89（95％CI 0.65–1.22）和0.95（95％CI 0.73-1.25），严重系统性事件的风险分别增加了17％（95％CI 6％–27％，p = 0.0042）与任何统计范围的统计范围相比，致命的伪像，眼睛严重不良，死亡血管和所有原因。
Bevacizumab不优于Ranibizumab作为视力的治疗方法，在选择严重的全身性事件的风险中，在选择Bevacizumab和Ranibizumab之间需要使用ofhthalmic疾病，这是必要的。
Bevacizumab is believed to be as effective and safe as ranibizumab for ophthalmic diseases; however, its magnitude of effectiveness and safety profile remain controversial. Thus, a meta-analysis and systematic review appears necessary. PubMed and EMBASE were systematically searched with no restrictions. All relevant citations comparing ranibizumab and bevacizumab were considered for inclusion. Pooled effect estimates were obtained using a fixed- and random-effects meta-analysis. Nine independent randomised-controlled clinical trials (RCTs) involving 2,289 participants were identified. Compared with bevacizumab, the overall combined weighted mean difference (WMD) of the mean change in visual acuity for ranibizumab was 0.52 letters (95% CI −0.11–1.14). The odds ratios (ORs) of gaining ≥15, gaining 5–14, losing 5–14 and losing ≤15 letters were 1.10 (95% CI 0.90–1.33), 0.93 (95% CI 0.77–1.11), 0.89 (95% CI 0.65–1.22) and 0.95 (95% CI 0.73–1.25), respectively. The risk of serious systemic events increased by 17% (95% CI 6%–27%, p = 0.0042) for bevacizumab treatment in comparison with ranibizumab. No statistically significant differences between the two treatments were found for the nonfatal arterial thrombotic events, ocular serious adverse, death from vascular and all causes events. Bevacizumab is not inferior to ranibizumab as a treatment for achieving visual acuity. The use of bevacizumab was associated with an increased risk of developing serious systemic events. Weighing the costs and health outcomes is necessary when selecting between bevacizumab and ranibizumab for ophthalmic diseases. Due to the limitations of the available data, further research is needed.
登录
查看更多内容
DOI：
10.1136/bmj.e5182
发表时间：
2012-08-13
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Ford JA;Elders A;Shyangdan D;Royle P;Waugh N
通讯作者：
Waugh N
影响因子：
--
作者：
Curtis, Lesley H.;Hammill, Bradley G.;Cousins, Scott W.
通讯作者：
Cousins, Scott W.
影响因子：
1.6
作者：
Hufendiek, Katerina;Hufendiek, Karsten;Gamulescu, Maria-Andreea
通讯作者：
Gamulescu, Maria-Andreea
影响因子：
--
作者：
Cho HJ;Baek JS;Lee DW;Kim CG;Kim JW
通讯作者：
Kim JW
影响因子：
4.2
作者：
Brechner, Ross J.;Rosenfeld, Philip J.;Caplan, Stuart
通讯作者：
Caplan, Stuart